Publications by authors named "Zengxin Yang"
Introduction: To explore the optimal dosage of tirofiban associated with double benefits of efficacy and safety in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) undergoing early percutaneous coronary intervention (PCI).
Aims: A total of 163 patients were included in this study (78 in SD group versus 85 in HD group). In SD (HD) group, tirofiban was administered intravenously with a bolus dose of 10 (5) μg/kg within 3 min and followed by continuous intravenous infusion of 0.
Article Synopsis
- The study aimed to determine if taking high-dose atorvastatin before undergoing emergency percutaneous coronary intervention (PCI) could reduce the risk of contrast-induced nephropathy (CIN) in patients with acute ST-segment elevation myocardial infarction (STEMI).
- Patients were randomly assigned to receive either 80 mg of atorvastatin or a placebo before the procedure, with results showing that only 2.6% of the atorvastatin group developed CIN compared to 15.7% in the placebo group (statistically significant).
- Additionally, the atorvastatin group showed better renal function post-procedure, and the results suggest that pretreatment with atorvastatin significantly lowers the risk of developing CIN in these patients.